France

OSE Immunotherapeutics SA

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

Chinaplas 2020

Participation Not Confirmed

Update your events

OSE Immunotherapeutics Receives Grant to Advance COVID-19 Vax

Lead Product(s): Covepit

Therapeutic Area: Infections and Infectious Diseases Product Name: Covepit

Highest Development Status: Preclinical Product Type: Vaccine

Partner/Sponsor/Collaborator: Nantes Metropole

Deal Size: $0.2 million Upfront Cash: Undisclosed

Deal Type: Funding July 16, 2020

Details:

OSE is working on the development of a prophylactic vaccine against the pandemic virus SARS-CoV-2. This research program aims to develop a prophylactic vaccine focused on memory T cells and based on a multiepitope- peptide approach.

Antabio

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

Chinaplas 2020

Participation Not Confirmed

Update your events

Antabio Receives QIDP Designation From the U.S. FDA for the Development of MEM-ANT3310

Lead Product(s): ANT3310,Meropenem

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 06, 2020

Details:

QIDP is granted to Antabio's MEM-ANT3310 for major hospital indications including nosocomial pneumonia.

OSE Immunotherapeutics SA

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

Chinaplas 2020

Participation Not Confirmed

Update your events

OSE Immunotherapeutics Announces COVID-19 Prophylactic Vaccine Program

Lead Product(s): Peptide vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 05, 2020

Details:

Vaccine leverages expertise in peptide selection and optimization and proprietary Memopi® technology to explore a T lymphocyte immune response for COVID-19.

MedinCell

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

Chinaplas 2020

Participation Not Confirmed

Update your events

MedinCell Has Launched a COVID-19 Research Initiative Based on Its Experience to Formulate Long-Acting Injectable Ivermectin

Lead Product(s): Ivermectin

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 06, 2020

Details:

Study reveal that antiparasitic drug Ivermectin can kill coronavirus in a laboratory setting in under 48 hours. A single treatment is able to effect ?5000-fold reduction in 48h in cell culture.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

OSE Immunotherapeutics SA

OSE Immunotherapeutics Receives Grant to Advance COVID-19 Vax

Antabio

Antabio Receives QIDP Designation From the U.S. FDA for the Development of MEM-ANT3310

OSE Immunotherapeutics SA

OSE Immunotherapeutics Announces COVID-19 Prophylactic Vaccine Program

MedinCell

MedinCell Has Launched a COVID-19 Research Initiative Based on Its Experience to Formulate Long-Acting Injectable Ivermectin